Cargando…

Design, synthesis, and anticancer activity of three novel palbociclib derivatives

Cancer is one of the most serious diseases threatening human health, so it is particularly important to develop effective tumor-targeting drugs. As the first CDK4/6 inhibitor, palbociclib effectively inhibits tumor proliferation by blocking the cell cycle to the G1 phase. 10-HCPT is a Topo I inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tian, Zhou, An-Di, Bai, Li-Fei, Zhang, Xiao-Yang, Zhou, Yu-Ting, Yang, Hai-Li, Xu, Le-Tian, Guo, Xin-Qin, Zhu, Xi-Yu, Wang, Dong-Jin, Gu, Hong-Wei, Wang, Xiao-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453454/ https://www.ncbi.nlm.nih.gov/pubmed/36091173 http://dx.doi.org/10.3389/fonc.2022.959322

Ejemplares similares

Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib
por: Nelson, Kellie Lynn, et al.
Publicado: (2017)

Palbociclib-Induced Pneumonitis: A Case Report and Review of the Literature
por: Sarkisian, Saro, et al.
Publicado: (2020)

PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates
por: Xu, Bing, et al.
Publicado: (2018)

Cystatin-B Negatively Regulates the Malignant Characteristics of Oral Squamous Cell Carcinoma Possibly Via the Epithelium Proliferation/Differentiation Program
por: Xu, Tian-Tian, et al.
Publicado: (2021)

Synthesis and Anticancer Activity Evaluation of Novel Phenanthridine Derivatives
por: Wan, Minghui, et al.
Publicado: (2019)

Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
por: Poumeaud, François, et al.
Publicado: (2022)

Corrigendum: Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
por: Poumeaud, François, et al.
Publicado: (2023)

A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy
por: Yu, Yu-Chong, et al.
Publicado: (2022)

Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients
por: Li, Xiao-fei, et al.
Publicado: (2021)

High-Throughput Strategies for the Discovery of Anticancer Drugs by Targeting Transcriptional Reprogramming
por: Huang, Lijun, et al.
Publicado: (2021)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
por: Mao, Yan, et al.
Publicado: (2023)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways
por: Wu, Qiong, et al.
Publicado: (2021)

Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
por: Jost, Tina, et al.
Publicado: (2021)

The function of natural compounds in important anticancer mechanisms
por: Nan, Yang, et al.
Publicado: (2023)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
por: Brufsky, Adam, et al.
Publicado: (2022)

Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway
por: Qin, Ge, et al.
Publicado: (2015)

The Role of Non-Coding RNAs in Breast Cancer Drug Resistance
por: Tian, Jin-hai, et al.
Publicado: (2021)

Design, Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives
por: Guan, Yong-Feng, et al.
Publicado: (2021)

KDM5C Represses FASN-Mediated Lipid Metabolism to Exert Tumor Suppressor Activity in Intrahepatic Cholangiocarcinoma
por: Zhang, Bo, et al.
Publicado: (2020)

A quantitative model based on gross tumor volume of gastric adenocarcinoma corresponding to N-stage measured at multidetector computed tomography for preoperative determination of resectability: A case control study
por: Yu, Zi-yi, et al.
Publicado: (2022)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

Identification METTL18 as a Potential Prognosis Biomarker and Associated With Immune Infiltrates in Hepatocellular Carcinoma
por: Li, Tian-Hao, et al.
Publicado: (2021)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Relationship between NUDT21 mediated alternative polyadenylation process and tumor
por: Xiao, Shan, et al.
Publicado: (2023)

RGB Three-Channel SWE-Based Ultrasomics Model: Improving the Efficiency in Differentiating Focal Liver Lesions
por: Cheng, Mei-Qing, et al.
Publicado: (2021)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer
por: Wang, Tao, et al.
Publicado: (2022)

Machine learning models predict lymph node metastasis in patients with stage T1-T2 esophageal squamous cell carcinoma
por: Li, Dong-lin, et al.
Publicado: (2022)

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
por: Yu, Yang, et al.
Publicado: (2022)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial
por: Galactionova, Katya, et al.
Publicado: (2022)

Design, synthesis and anticancer activity of naphthoquinone derivatives
por: Shen, Xiao-bao, et al.
Publicado: (2020)

NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer
por: Li, Xiao-qin, et al.
Publicado: (2019)

Gross tumor volume of adenocarcinoma of esophagogastric junction corresponding to cT and cN stages measured with computed tomography to quantitatively determine resectabiliy: A case control study
por: Li, Ke-ying, et al.
Publicado: (2022)

Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
por: Jin, Ming-Zhu, et al.
Publicado: (2018)

Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study
por: Lei, Yin, et al.
Publicado: (2022)

AMBRA1 and its role as a target for anticancer therapy
por: Li, Xiang, et al.
Publicado: (2022)

Study protocol for comparing the efficacy of left-open single-flap technique versus double-flap technique after proximal gastrectomy: A multicenter randomized controlled trial
por: Yang, Qin Chuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bcmseajobobg56kmgdiqsu5dju